Roger J. Pomerantz, MD, FACP

Roger J. Pomerantz, MD, FACP has extensive work experience in the biotechnology and pharmaceutical industry. Roger J. is currently serving as the President, CEO, and Chairman of ContraFect Corp, a clinical-stage biotechnology company focused on combating drug-resistant bacterial pathogens. Roger J. played a crucial role in successfully leading ContraFect's IPO on the NASDAQ.

In addition, Dr. Pomerantz holds various leadership positions in other companies. Roger J. is the Founding Chairman of the Board of Directors at Indaptus Therapeutics Inc. and also serves as the Chairman of the Board of Directors at Viracta Therapeutics, Inc. and CollPlant.

Dr. Pomerantz is a Senior Clinical Advisor to the Board of Directors and, previously, the Founding Chairman of the Board of Directors at Seres Therapeutics, a prominent microbiome-focused biopharmaceutical company. Roger J. has also held the position of President, CEO, and Chairman at Seres Therapeutics.

Furthermore, Dr. Pomerantz is involved in strategic advisory roles. Roger J. serves as a Senior Strategic Advisor at OM Pharma and has been a Founding Director of the Board of Directors at X-Vax Technology, Inc. and VerImmune.

Additionally, Dr. Pomerantz played a key role as the Founding Chairman of the Board of Directors at Silicon Therapeutics, a biotechnology company utilizing quantum physics in drug design and development. The company was acquired by Roivant Inc. in 2021.

Lastly, Dr. Pomerantz has served as the Chairman of the Scientific Advisory Board at Aridis Pharmaceuticals, a biotechnology company specializing in infectious diseases.

Overall, Dr. Roger J. Pomerantz has a diverse background and extensive experience in leadership positions within the biotechnology and pharmaceutical industry.

Roger J. Pomerantz, MD, FACP has an extensive education history in the medical field. Roger J. attended The Johns Hopkins University from 1975 to 1978, where they obtained a BA in Biochemistry. Following this, they attended The Johns Hopkins University School of Medicine from 1979 to 1982, earning their MD degree in Medicine.

Dr. Pomerantz then went on to complete their internship, junior and senior residency in Medicine, and fellowship in Infectious Diseases and Virology at Massachusetts General Hospital and Harvard Medical School from 1982 to 1987.

In 1985, while still in residency, they obtained their certification in Internal Medicine from the Board of Internal Medicine. Subsequently, they pursued further education at the Harvard Medical School, serving as an Instructor in Medicine and Pediatrics from 1985 to 1990, with a focus on Virology.

From 1987 to 1988, Dr. Pomerantz also served as the Chief Resident at Harvard Medical School - Massachusetts General Hospital. Expanding their research expertise, they pursued a Post Doctoral Fellowship in Molecular Virology at the Whitehead Institute of Biomedical Research of Massachusetts Institute of Technology (MIT) from 1988 to 1990, where they are credited with creating the first Molecular Model of HIV Latency (Cell 1990).

Additionally, Dr. Pomerantz obtained further certifications throughout their career. Roger J. became board-certified in Infectious Diseases by the Infectious Diseases Society of America in January of 1995. Roger J. also obtained their medical license from the State of Pennsylvania in January of 1990. Finally, they acquired their certification in Internal Medicine from the Board of Internal Medicine in January of 1985.

Overall, Dr. Roger J. Pomerantz possesses a wealth of educational achievements and certifications, making him highly qualified in the field of medicine, particularly in the areas of Infectious Diseases and Virology.